about
The glomerulosclerosis gene Mpv17 encodes a peroxisomal protein producing reactive oxygen speciesAspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cellsSuperoxide anions and endothelial cell proliferation in normoglycemia and hyperglycemia.Therapeutic approaches for ischemia/reperfusion injury in the liver.Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells.Functional rescue of the glomerulosclerosis phenotype in Mpv17 mice by transgenesis with the human Mpv17 homologue.Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsThe enigmatic roles of caspases in tumor developmentOverexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cellsBetulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy.Both human and mouse mesenchymal stem cells promote breast cancer metastasis.TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.A non-apoptotic role for caspase-9 in muscle differentiation.MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release.In situ trapping of initiator caspases reveals intermediate surprises.Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells.AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.Gene therapy for colon cancer.Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity.Overexpression of human superoxide dismutase inhibits oxidation of low-density lipoprotein by endothelial cells.Adenovirus-mediated manganese superoxide dismutase gene transfer to hamster cheek pouch carcinoma cells.Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis.Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation.Development of a FACS-based Smac/DIABLO release assay to monitor individual drug responses and to pave the way towards patient-tailored therapies.Loss of auditory function in transgenic Mpv17-deficient mice.Effects of antioxidant enzyme overexpression on the invasive phenotype of hamster cheek pouch carcinoma cells.Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c releaseRecombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunctionAge-dependent hypertension in Mpv17-deficient mice, a transgenic model of glomerulosclerosis and inner ear diseaseIschemia/reperfusion injury in the liver of BALB/c mice activates AP-1 and nuclear factor kappaB independently of IkappaB degradationVitamin D3-24-hydroxylase (CYP24) as a potential target for intervention with diabetic and nondiabetic nephropathy[Gene therapy strategies for colorectal cancer]
P50
Q24336548-55BD0E72-6F24-4445-B5E3-6C98E563CDF4Q28183225-0F6AF430-9567-4501-82B0-29B540DC8234Q31825675-E17C8904-127A-4C52-9B49-D7E42372E326Q33763851-84EB997C-8C4B-4934-A8B6-87D4F0C659FDQ33925097-B57669BB-FBAA-43AC-9AE8-8507E6B41FD4Q34295898-484D2F3C-D753-4B3A-80AA-B96EDA5CE5F3Q34467287-0322BDDD-8D13-4478-A36F-EE00E5696519Q36215003-EA0FC8AB-CA19-4C00-8A1D-DDB0159B4548Q37073589-C550F325-9A2E-4560-824A-7C8EB051EC4FQ37342739-809C7062-DF02-46B6-B5C6-81E9EBC6FBD9Q37679126-42AEA7DD-C023-4C6B-93D7-F3E99A1FAC8AQ38323803-861B50C0-6935-4999-AE7C-D2CFACC9F448Q39505707-81C5CCE0-826D-4CEF-A65D-CEDCFC001B47Q39645187-726B1723-B7E3-47D5-96BB-09803359A75DQ39649739-F2000E2E-2AD5-4556-A677-7A62B62A1306Q39862039-7FB0EC14-9CFE-4327-9ABD-1D374E73A964Q39924087-10EA3B61-E124-4659-B209-E158A96F4815Q40102576-35DB7A71-AAD3-4FC9-AAE4-D0C2FF5AFB53Q40188536-CACF2A69-DE4B-4DBB-AC33-A0806C849E4AQ40218268-A4B48D4A-058F-4771-BFA1-8CF4C40BE749Q40582634-C4C2F168-7136-4CC4-B5D8-294781A83575Q40849028-D3D2455E-6A7F-412D-8ED1-676591E61F40Q41051027-3C18820F-EEC7-4E0D-A084-F0B956258F03Q43827486-FB2EEDD8-1446-46C0-B7AB-7563991A88EBQ44115873-67814CA0-9BC2-4F6F-8D47-1706CCD81FB1Q45856291-3BA99D5D-D30A-4E15-B467-76F2DBB1CE53Q45887796-3EF76646-5494-4F0C-984D-1AA2B33657C8Q46872442-A2F95E31-259C-454B-8C1F-6B97FD82D3DFQ48553142-27AA31B7-7411-4E4E-A265-D8DDAD16C012Q51192946-257E80F2-950F-44BB-A101-B578BC38ABFAQ53867825-3F6EA40F-9AE0-4516-96EC-039214AAC8D5Q55469625-053643DB-3077-4175-B1A5-E6EA3D7BEF4DQ57384595-5D601703-0B09-42B7-BE10-09039F4FEDC4Q64381763-23BAE225-8B26-4014-AD45-55ADE3E5E69BQ73444896-A5CCA75E-65A9-450E-B3C1-6C040FCAE4EFQ77355587-FC66DB14-E308-4ED7-8DBD-01B38F2EC40AQ79834427-819FC9B6-0CF3-433A-8866-A01A18E36B43Q79889958-B42B7487-B0FC-462C-AAFF-E80105AD96EB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ralf Michael Zwacka
@ast
Ralf Michael Zwacka
@en
Ralf Michael Zwacka
@es
Ralf Michael Zwacka
@nl
type
label
Ralf Michael Zwacka
@ast
Ralf Michael Zwacka
@en
Ralf Michael Zwacka
@es
Ralf Michael Zwacka
@nl
prefLabel
Ralf Michael Zwacka
@ast
Ralf Michael Zwacka
@en
Ralf Michael Zwacka
@es
Ralf Michael Zwacka
@nl
P106
P31
P496
0000-0003-2821-0387